Literature DB >> 7788848

Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol.

M C Bosland1, H Ford, L Horton.   

Abstract

This study determined the incidence of prostate adenocarcinoma following long-term treatment of NBL and Sprague-Dawley rats with estradiol-17 beta or diethylstilbestrol (DES) plus testosterone and it defined the origin of these tumors. NBL and Sprague-Dawley rats were treated with two Silastic tubing implants (i.d. 1.6 mm, o.d. 3.2 mm) containing a 2 cm long filling of testosterone and one implant containing a 1 cm long filling of estradiol-17 beta or DES. Control animals received empty implants. Treated animals were killed when moribund and controls were killed at 91 (NBL) or 75 (Sprague-Dawley) weeks after initiation of treatment and accessory sex glands were sampled for histopathological examination of multiple step sections. Prostatic adenocarcinoma occurred in 100% of NBL rats after treatment with estradiol-17 beta or DES plus testosterone for 44 and 59 weeks (group means) respectively. Adenocarcinoma incidences were lower in Sprague-Dawley rats. The adenocarcinomas were small, microscopic, invasive tumors and they were spatially closely associated with the periurethral ducts of the dorsal, lateral and/or anterior (= coagulating gland) prostate, but never with the ducts of the ventral lobe and seminal vesicles. One adenocarcinoma was of uncertain origin. Duct-acinar dysplastic lesions occurred in the periphery of the dorsal and lateral prostate of all hormone-treated NBL and many Sprague-Dawley rats, but did not appear to give rise to carcinoma. Although some adenocarcinomas were contiguous with dysplastic ducts of the peripheral dorsolateral prostate, the main mass of these neoplasms was located in the periurethral area. Also, most adenocarcinomas were only connected with the periurethral ducts, in which atypical hyperplasia occurred following hormone treatment for 36 weeks or longer. Thus atypical hyperplasia of the periurethral prostate ducts, but not peripheral duct-acinar dysplasia, appeared to be the likely precursor of the induced carcinomas. Testosterone plus DES, but not estradiol-17 beta, induced marked dysplasia-like lesions in the acini of the ventral prostate of all NBL and many Sprague-Dawley rats. These lesions had progressed to carcinoma in situ (or adenoma) in 46% of NBL rats.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7788848     DOI: 10.1093/carcin/16.6.1311

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  54 in total

1.  Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth.

Authors:  Neville N C Tam; Ying Gao; Yuet-Kin Leung; Shuk-Mei Ho
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

Review 2.  The molecular etiology and prevention of estrogen-initiated cancers: Ockham's Razor: Pluralitas non est ponenda sine necessitate. Plurality should not be posited without necessity.

Authors:  Ercole Cavalieri; Eleanor Rogan
Journal:  Mol Aspects Med       Date:  2013-08-30

3.  Selenomethionine and alpha-tocopherol do not inhibit prostate carcinogenesis in the testosterone plus estradiol-treated NBL rat model.

Authors:  Nur Ozten; Lori Horton; Salamia Lasano; Maarten C Bosland
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-23

Review 4.  Developmental estrogen exposures predispose to prostate carcinogenesis with aging.

Authors:  Gail S Prins; Lynn Birch; Wan-Yee Tang; Shuk-Mei Ho
Journal:  Reprod Toxicol       Date:  2006-10-24       Impact factor: 3.143

5.  The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention.

Authors:  Maarten C Bosland
Journal:  Rev Urol       Date:  2005

6.  Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.

Authors:  I Leav; K M Lau; J Y Adams; J E McNeal; M E Taplin; J Wang; H Singh; S M Ho
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 7.  Perinatal exposure to oestradiol and bisphenol A alters the prostate epigenome and increases susceptibility to carcinogenesis.

Authors:  Gail S Prins; Wan-Yee Tang; Jessica Belmonte; Shuk-Mei Ho
Journal:  Basic Clin Pharmacol Toxicol       Date:  2008-02       Impact factor: 4.080

8.  Sex hormones induce direct epithelial and inflammation-mediated oxidative/nitrosative stress that favors prostatic carcinogenesis in the noble rat.

Authors:  Neville N C Tam; Irwin Leav; Shuk-Mei Ho
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

9.  L-selenomethionine does not protect against testosterone plus 17β-estradiol-induced oxidative stress and preneoplastic lesions in the prostate of NBL rats.

Authors:  Nur Özten; Michael Schlicht; Alan M Diamond; Maarten C Bosland
Journal:  Nutr Cancer       Date:  2014-04-28       Impact factor: 2.900

10.  Bisphenol A Disrupts HNF4α-Regulated Gene Networks Linking to Prostate Preneoplasia and Immune Disruption in Noble Rats.

Authors:  Hung-Ming Lam; Shuk-Mei Ho; Jing Chen; Mario Medvedovic; Neville Ngai Chung Tam
Journal:  Endocrinology       Date:  2015-10-23       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.